{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-029955","form_type":"8-K","ticker":"NKTX","cik":"0001787400","company_name":"Nkarta, Inc.","filed_at":"2023-06-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.581654+00:00","generated_at":"2026-06-13T16:26:39.091085+00:00","sec_items":["8.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Nkarta NKX101 achieves 67% CR/CRi in AML Phase 1 with modified lymphodepletion","bullets":["In Flu/Ara-C cohort (n=6), NKX101 showed 67% CR/CRi rate (4/6) and 50% CR rate (3/6); 2 CRs MRD-negative.","In Flu/Cy highest-dose cohort (n=18), CR/CRi rate was 22% (4/18) and CR rate 17% (3/18).","NKX101 well tolerated; no dose-limiting toxicities, limited CRS/ICANS/GvHD across all doses.","Expansion cohort with Flu/Ara-C to enroll 12-20 more patients; clinical update expected 1H 2024.","Patients heavily pre-treated (median 2 prior lines, 90%+ prior venetoclax); majority poor-risk disease."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-029955","json":"https://secwatch.observer/filing/0000950170-23-029955.json","markdown":"https://secwatch.observer/filing/0000950170-23-029955.md","text":"https://secwatch.observer/filing/0000950170-23-029955.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023029955/0000950170-23-029955-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787400/000095017023029955/nktx-20230627.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T16:26:39.091085+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}